CEO John Oyler liquidates entire 4,940-share position at $270.56 average for $1.3M; stock down 15.2% in 30 days, 31.6% from high.
John Oyler, CEO of BeOne Medicines Ltd. (ONC), executed two separate sales totaling 4,940 shares for $1,336,547.58, completely liquidating his shareholding. The sales occurred at a blended average price of $270.56 on 2026-06-08. This total liquidation is notable given the stock's recent price deterioration: the current price of $263.61 represents a -15.2% decline over 30 days and a -31.6% drop from the 52-week high of $385.22. While the CEO's cross-ticker track record shows his prior sells achieved well-timed outcomes (90d well-timed rate of 100.00%), his five prior sales at ONC specifically (conducted on 2025-12-16) all exhibited 90-day declines ranging from -3.7% to -4.8%, suggesting a pattern of selling ahead of downward price moves at this ticker. The complete exit of holdings by the chief executive during a period of material stock weakness warrants close examination.